https://www.selleckchem.com/pr....oducts/phorbol-12-my
Purpose Multiple myeloma (MM) treatment has changed tremendously, with significant improvement in patient out-comes. One group with a suboptimal benefit is patients with high-risk cytogenetics, as tested by conventional karyotyping or fluorescence in situ hybridization (FISH). Methodology for these tests has been published, but not necessarily standardized. Methods We address variability in the testing and reporting methodology for MM cytogenetics in the United States using the ongoing African American Multiple M
Like
Comment
Share
